Yükleniyor... / Loading...
This study looks at determining RAS mutation status through liquid biopsies (blood samples) in patients with metastatic colorectal cancer who are RAS wild-type and starting first-line treatment. It enrolled people aged 18 and older with histologically confirmed metastatic disease. It was conducted as a study without a phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion criteria: * Subjects who give their informed consent in writing * Subjects with metastatic colorectal cancer, measurable by RECIST, who start first-line treatment * Male and female subjects, at least 18 years of age and of any ethnicity * Subjects with a histologically-confirmed diagnosis of colorectal carcinoma with metastatic disease and wild-type RAS. Exclusion criteria: * Pregnant or breastfeeding women * Subjects who have previously received monoclonal antibodies against EGFR (cetuximab or panitumumab), small-molecule EGFR inhibitors (such as erlotinib) or other biological cancer treatments * History of another solid or haematological tumour in the previous 5 years, except a history of basal cell carcinoma of the skin or pre-invasive cervical cancer * Subjects who are participating or have participated in a clinical trial in the 30 days prior to inclusion.